Transgenic mice expressing the PS1-A246E mutation: Effects on spatial learning, exploration, anxiety, and motor coordination

Behavioural Brain Research

Volumn 138, Issue 1, 2003, Pages 71-79

  Lalonde, Robert ^a,d   Qian, S ^b   Strazielle, C ^c  

^a UNIVERSITÉ DE ROUEN   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITÉ DE LORRAINE   (France)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Alzheimer's disease; Anxiety; Motor activity; Presenilin 1; Spatial orientation; Spontaneous alternation

Indexed keywords

AMYLOID BETA PROTEIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; FEMALE; GENE MUTATION; LEARNING; MALE; MAZE TEST; MOBILIZATION; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PLAQUE FORMING CELL; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SPATIAL ORIENTATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AROUSAL; CHROMOSOMAL PROTEINS, NON-HISTONE; EXPLORATORY BEHAVIOR; FEMALE; HUMANS; MAZE LEARNING; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOTOR SKILLS; MUSCULOSKELETAL EQUILIBRIUM; MUTATION; NEURAL INHIBITION; ORIENTATION; PRESENILIN-1; REACTION TIME;

EID: 0037421111     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(02)00230-9     Document Type: Article

References (49)

1. Arendash G.W., King D.L., Gordon M.N., Morgan D., Hatcher J.M., Hope C.E., et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891:2001;42-53.
2. Barrow P.A., Empson R.M., Gladwell S.J., Anderson C.M., Killick R., Yu X., et al. Functional phenotype in transgenic mice expressing human mutant presenilin-1. Neurobiol. Dis. 7:2000;119-126.
3. Begley J.G., Duan W., Chan S., Duff K., Mattson M.P. Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice. J. Neurochem. 72:1999;1030-1039.
4. Borchelt D.R., van Lare J., Lee M.K., Gonzalez V., Jenkins N.A., Copeland N.G., et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 19:1997;939-945.
5. Braak H., Braak E. Cortical destruction and cell death in Alzheimer's disease. Koliatsos V.E., Ratan R.R. Cell Death and Diseases of the Nervous System. 1999;497-510 Humana, Totowa NJ.
6. Campion D., Brice A., Dumanchin C., Puel M., Baulac M., De La Sayette V., et al. A novel presenilin 1 mutation in familial Alzheimer's disease with an onset age of 29 years. NeuroReport. 7:1996;1582-1584.
7. Chen J.Y., Stern Y., Sano M., Mayeux R. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease. Arch. Neurol. 48:1991;1141-1143.
8. Chui D.-H., Tanahashi H., Ozawa K., Ikeda S., Checler F., Ueda O., et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nature Med. 5:1999;560-564.
9. Chung J.A., Cummings J.L. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease. Neurol. Clin. 18:2000;829-846.
10. Citron M., Westway D., Xia W., Carlson G., Diehl T., Levesque G., et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nature Med. 3:1997;67-72.
11. Czech C., Tremp G., Pradier L. Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms. Prog. Neurobiol. 60:2000;363-384.
12. Czech C., Lesort M., Tremp G., Terro F., Blanchard V., Schombert B., et al. Characterization of human presenilin 1 transgenic rats: increased sensitivity to apoptosis in primary neuronal cultures. Neuroscience. 87:1998;325-336.
13. Davis J.A., Naruse S., Chen H., Eckman C., Younkin S., Price D.L., et al. An Alzheimer's disease-linked PS1 variant rescues the developmental abnormalities of PS1-deficient embryos. Neuron. 20:1998;603-609.
14. Dember W.N., Fowler H. Spontaneous alternation behavior. Psychol. Bull. 55:1958;412-428.
15. Duff K., Eckman C., Zehr C., Yu X., Prada C.-M., Perez-tur J., et al. Increased β-amyloid42(43) in brains of mice expressing mutant presenilin-1. Nature. 383:1996;710-713.
16. Eckert A., Schindowski K., Leutner S., Luckhaus C., Touchet N., Czech C., et al. Alzheimer's disease-like alterations in peripheral cells from presenilin-1 transgenic mice. Neurobiol. Dis. 8:2001;331-342.
17. Frisoni G.B., Rozzini L., Gozetti A., Binetti G., Zanetti O., Bianchetti A., et al. Behavioral syndromes in Alzheimer's disease: description and correlates. Dement. Geriatr. Cogn. Disord. 10:1999;130-138.
18. Guo Q., Fu W., Sopher B.L., Miller M.W., Ware C.B., Martin G.M., et al. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nature Med. 5:2000;101-106.
19. Guo Q., Sebastian L., Sopher B.L., Miller M.W., Ware C.B., Martin G.M., et al. Increased vulnerability of hippocampal neurons from presenilin-1 mutant knock-in mice to amyloid β-peptide toxicity: central roles of superoxide production and caspase activation. J. Neurochem. 72:1999;1019-1029.
20. Holcomb L.A., Gordon M.N., McGowan E., Yu X., Benkowic S., Jantzen P., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin transgenes. Nature Med. 4:1998;97-100.
21. Holcomb L.A., Gordon M.N., Jantzen P., Hsaio K., Duff K., Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav. Genet. 29:1999;177-185.
22. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron. 13:1994;45-53.
23. Jack C.R., Petersen R.C., Xu Y., O'Brien P.C., Smith G.E., Ivnik R.J., et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology. 51:1998;993-999.
24. NTR cholinergic basal forebrain septohippocampal pathway. Exp. Neurol. 170:2001;227-243.
25. Janus C., D'Amelio S., Amitay O., Chishti M.A., Strome R., Fraser P., et al. Spatial learning in transgenic mice expressing presenilin 1 (PS1) transgenes. Neurobiol. Aging. 21:2000;541-549.
26. Kalaria R.N., Harshbarger-Kelly M., Cohen D.L., Premkumar D.R.D. Molecular aspects of inflammatory and immune responses in Alzheimer's disease. Neurobiol. Aging. 17:1996;687-693.
27. Kang D.E., Soriano S., Frosch M.P., Collins T., Naruse S., Sisodia S.S., et al. Presenilin 1 facilitates the constitutive turnover of β-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the β-catenin-signalling pathway. J. Neurosci. 19:1999;4229-4237.
28. Kurt M.A., Davies D.C., Kidd M., Duff K., Rolph S.C., Jennings K.H., et al. Neurodegenerative changes associated with β-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Exp. Neurol. 171:2001;59-71.
29. Lalonde R. Motor abnormalities in staggerer mutant mice. Exp. Brain Res. 68:1987;417-420.
30. Lalonde R., Dubois M., Strazielle C., Eyer J. Motor coordination and spatial orientation are affected by neurofilament maldistribution: correlations with regional brain activity of cytochrome oxidase. Exp. Brain Res. 126:1999;223-234.
31. Lalonde R, Dumont M, Sturchler-Pierrat C, Staufenbiel M, Strazielle C. Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res 2002, in press.
32. Lamb B.T., Bardel K.A., Kulkane L.S., Anderson J.J., Holtz G., Wagner S.L., et al. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome mice. Nature Neurosci. 2:1999;695-697.
33. Leutner S., Czech C., Schindowski K., Touchet N., Eckert A., Müller W.E. Reduced antioxidant enzyme activity in brains of mice transgenic for human presenilin-1 with single or multiple mutations. Neurosci. Lett. 292:2000;87-90.
34. Matsuoka Y., Picciano M., La François J., Duff K. Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience. 104:2001;609-613.
35. McGowan E., Sanders S., Iwatsubo T., Takeuchi A., Saido T., Zehr C., et al. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis. 6:1999;231-244.
36. Morris R.G.M., Garrud P., Rawlins J.P., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 292:1982;681-683.
37. Parent A., Linden D.J., Sisodia S.S., Borchelt D.R. Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1. Neurobiol. Dis. 6:1999;56-62.
38. Parvizi J., Van Hoesen G.W., Damasio A. The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann. Neurol. 49:2000;53-66.
39. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14:1985;149-167.
40. Price J.L., Ko A.I., Wade M.J., Tsou S.K., McKeel D.W., Morris J.C. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 58:2001;1395-1402.
41. Qian S., Jiang P., Guan X.-M., Singh G., Trumbauer M.E., Yu H., et al. Mutant human presenilin-1 protects presenilin 1 null mouse against embryonic lethality and elevates Aβ1-42/43 production. Neuron. 20:1998;611-617.
42. Salat D.H., Kaye J.A., Janowsky J.S. Selective preservation and degeneration within the prefrontal cortex in aging and Alzheimer disease. Arch. Neurol. 58:2001;1403-1408.
43. Selkoe J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31.
44. Siman R., Reaume A.G., Savage M.J., Trusko S., Lin Y.-G., Scott R.W., et al. Presenilin-1 P264L knock-in mutation: differential effects on Aβ production, amyloid deposition, and neuronal vulnerability. J. Neurosci. 20:2000;8717-8726.
45. van Leuven F. Single and multiple transgenic mice as models for Alzheimer's disease. Prog. Neurobiol. 61:2000;305-312.
46. Weintraub S., Mesulam M.M. Four neuropsychological profiles in dementia. Spinnler H., Boller F. Handbook of Neuropsychology. 8:1993;253-282 Elsevier, Amsterdam.
47. Wong T.P., Debeir T., Duff K., Cuello A.C. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J. Neurosci. 19:1999;2706-2716.
48. Zaman S.H., Parent A., Laskey A., Lee M.K., Borchelt D.R., Sisodia S.S., et al. Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial Alzheimer's disease mutation is normalized with a benzodiazepine. Neurobiol. Dis. 7:2000;54-63.
49. Zhu H., Guo Q., Mattson M.P. Dietary restriction protects hippocampal neurons against the death-promoting action of presenilin-1 mutation. Brain Res. 842:1999;224-229.